VistaGen expands executive severance plan to cover terminations without cause outside change-in-control events

• VistaGen Therapeutics adopted an amended change-in-control executive severance plan effective Oct. 7, 2026.
• Severance eligibility now covers involuntary termination without cause even when no change in control occurs.
• Cash severance set as base-salary multiples paid in a lump sum, tied to a defined severance period.
• COBRA support shifts to a lump-sum cash payment based on monthly premiums over a defined continuation period.
• Plan generally requires 12 months of full-time service; current executive officers qualify as eligible employees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065559), on October 09, 2026, and is solely responsible for the information contained therein.